Fish & Richardson Principal Jonathan Singer Named 2018 Life Sciences MVP of the Year by Law360

Fish & Richardson principal Jonathan Singer has been named a 2018 Life Sciences MVP of the Year by Law360. This is the fourth time that Singer, who heads Fish's life sciences litigation practice, has been singled out for a coveted MVP award. He was selected from nearly 1,000 submissions.

Singer conducted the winning oral argument for a stunning reversal of a $2.5 billion jury verdict - the largest patent damages award in history - against client Gilead Sciences. Hailed as one of the biggest litigation comebacks of all time, Fish won a "sparingly invoked" motion for judgment as a matter of law (JMOL) in March 2018 from Judge Leonard P. Stark - wiping out the jury's December 2016 $2.5 billion willful infringement verdict against Gilead - after proving that Idenix's patent was invalid due to lack of enablement. Judge Stark called Fish's enablement evidence "devastating" to Idenix.

Singer was a key member of the trial team that won a unanimous Federal Circuit opinion in April 2018 affirming the June 2016 post-trial reversal of a $200 million jury verdict against Gilead after proving Merck had forfeited its right to assert its hepatitis C drug patents against Gilead because of unclean hands. The case involved the company's blockbuster Sovaldi® and Harvoni® drugs, which cure hepatitis C.

Singer also won an important preliminary injunction in July 2018 for client Allergan preventing Sandoz from launching a generic version of Allergan's glaucoma treatment, Combigan®. Combigan has annual sales in excess of $200 million, and the patents do not expire until 2022. Singer and his team have been successfully litigating to preserve Allergan's product exclusivity since 2009.

Click here to read Singer’s MVP profile inLaw360 (subscription is required).